多潘立酮口腔崩解片崩解时限检查方法探讨

目的：探讨多潘立酮口腔崩解片崩解时限检查方法.方法：分别采用《中国药典》方法、量筒法和自制装置检查多潘立酮口腔崩解片崩解时限,并依据国家食品药品监督管理局药品审评中心颁布的《口腔崩解片的剂型特点和质量控制会议纪要》予以评价.结果：与其他两种方法相比,采用自制装置能更准确地检查多潘立酮口腔崩解片崩解时限,基本符合相关规定和要求,且与体内崩解时限检查具良好相关性.结论：本实验中自制装置适用于多潘立酮口腔崩解片崩解时限检查.     

高效液相色谱法测定多潘立酮片的含量

目的:建立高效液相色谱法测定多潘立酮片的含量。方法:采用SPHERI—5RP—18(220 4.6mm 5um)色谱柱,甲醇—水—三乙胺(60:40:0.5用冰醋酸调节pH值至4.3)为流动相,醋酸氯已定为内标,285nm为检测波长。结果:线性范围为6～60μg·ml~(-1)。在此范围内,浓度与峰面积线性关系良好(γ=0.9996),平均回收率为99.5％,RSD为0.48％(n=6)。结论:本法简便、准确、灵敏。     

三种药物防治胃肠肿瘤化疗所致呕吐的临床研究

目的：评价三种药物防治胃肠肿瘤化疗所致呕吐的价值。方法：９０名患者随机分成三组,灭吐灵组（Ａ组）,吗丁啉组（Ｂ组）,枢丹组（Ｃ组）。应用５－Ｆｕ＋ＬＶ方案化疗５天,观察５天内三种药物的止吐效果。结果：Ａ和Ｂ、Ｃ组比较有显著性差异（Ｐ〈０．０５）,Ｂ和Ｃ比较无显著性差异（Ｐ〉０．０５）。结论：Ｂ组副作用少,疗效高,建议临床推广使用吗丁啉。     

熊去氧胆酸在治疗胆汁反流性食管炎中的作用

目的 探讨熊去氧胆酸治疗胆汁反流性食管炎的疗效。方法 将186例患者随机分为3组：A组应用奥美拉唑20mg，2次／d；多潘立酮10mg，3次／d；治疗4周。B组应用熊去氧胆酸0．25g，2次／d；多潘立酮10mg，3次R／d；治疗4周。C组应用多潘立酮10mg，3次／d，治疗4周。服药1、2、4周时随访，分别观察3组症状改善情况。治疗4周后复查内镜、24h食管pH及胆汁监测。结果 A组与B组患者治疗后1、4周症状积分即显著降低（P〈0．01），C组治疗后症状积分也有降低（P〈0．05）。内镜检查：A组治愈率74．2％，有效率96．8％；B组治愈率71．0％，有效率91．9％；C组治愈率46．8％，有效率53．2％。A组、B组及C组治疗后24h食管酸暴露情况均显著改善，但A组在改善酸反流方面更明显（P〈0．01）；A组、B组治疗后食管胆汁反流均有显著改善，B组改善更明显（P〈0．01），C组对胆汁反流的改善不显著（P〉0．05）。结论 熊去氧胆酸联合应用质子泵抑制剂及促动力药治疗胆汁反流性食管炎疗效显著。     

中西医结合治疗功能性消化不良临床观察

目的:探讨中西医结合治疗功能性消化不良的临床疗效。方法:选取110例功能性消化不良患者为研究对象,随机分为两组,治疗组(n=55)采用中西医结合治疗,对照组(n=55)采用单纯西医治疗,观察两组治疗结果。结果:治疗组痊愈32例,好转21例,无效1例,总有效率为96.36%;对照组痊愈20例,好转28例,无效7例,总有效率为87.27%。治疗组疗效显著优于对照组,经比较,差异有统计学意义(P<0.05)。结论:中西医结合治疗功能性消化不良具有较好的临床疗效,值得临床推广应用。     

和胃方治疗糖尿病胃轻瘫临床对照研究

目的:对比中西药疗效,寻求糖尿病胃轻瘫的有效治疗方法。方法:60例随机分为中药组及西药组各30例。治疗前记录患者的症状评分,并行13C-辛酸呼气试验法测定胃固体半排空时间。中药组给予自拟和胃方口服,西药组给予多潘立酮,疗程4周。对两种疗法进行对比。结果:两组症状均改善(P0.01),胃固体排空速度均加快(P0.01)。中药组胃排空速度改善优于西药组(P0.01),胃轻瘫症状总体改善也优于西药对照组(P0.05),尤其上腹痛、排便异常和脘腹胀满、泛酸改善优于西药组(P0.01和P0.05)。结论:和胃方可有效改善胃轻瘫症状,提高胃排空速度,效果优于传统促动力药多潘立酮。     

中药联合多潘立酮治疗功能性消化不良分析

目的：探讨中药联合多潘立酮治疗功能性消化不良的临床效果。方法：选取2010年10月-2012年10月我院收治的90例功能性消化不良患者为研究对象,将其随机地分为对照组和治疗组,对照组45例单纯给予中药治疗,治疗组45例在对照组治疗的基础上给予中药联合多潘立酮治疗,对比两组患者临床治疗效果。结果：对照组患者总有效率为82.2%,治疗组患者总有效率为95.6%,两组对比差异明显,具有统计学意义（P〈0.05）。结论：与单纯运用中药治疗功能性消化不良相比,中药联合多潘立酮治疗临床效果明显,值得临床大力推广和应用。     

Comparison of a Fixed Combination of Domperidone and Paracetamol (Domperamol®) with Sumatriptan 50mg in Moderate to Severe Migraine: A Randomised UK Primary Care Study

Summary

Migraine is a common and debilitating condition routinely managed in primary care. A number of treatment options – both acute and prophylactic – are currently available but may differ in terms of efficacy, tolerability and cost. The aim of this study was to compare the effectiveness and tolerability of a fixed combination of domperidone and paracetamol (Domperamol; Servier), which has anti-nauseant and anti-emetic activity, with sumatriptan 50 mg in moderate to severe migraine. To do this, 120 patients were recruited from 23 primary care practices throughout the UK and were enrolled into the six-month trial. Patients were randomised at entry to one of the comparator regimens (used to treat their first migraine attack) and then crossed over to the alternative treatment for their second attack. Detailed diary cards were completed for each attack using a scale of pain severity. At two hours and four hours post-dose, the two treatments showed comparable efficacy (≤ 15% difference) in relieving headache and reducing nausea and vomiting. Both were well tolerated and there were no serious adverse effects. In the management of migraine patients typically seen in routine general practice, this trial showed that the effects of Domperamol and sumatriptan 50 mg were broadly comparable. Since Domperamol is considerably less expensive than sumatriptan (and other triptans), a first-line role for this agent appears appropriate.     

Domperidone plus paracetamol in the treatment of migraine

This study was designed to evaluate the safety and efficacy of domperidone in combination with paracetamol in the treatment of migraine. Severity of headache, duration of migraine attack and overall efficacy of treatment were amongst the variables assessed in a randomized, double-blind, three-way cross-over comparison of 1 g paracetamol plus either domperidone 30 mg, domperidone 20 mg or placebo, taken at onset of headache. Forty-six patients attending the City of London Migraine Clinic completed the study. A significant difference was observed in the duration of the migraine attack: a median of 17.5 h with paracetamol alone was reduced to 12.0 h with the addition of domperidone 20 mg, and to 12.0 h with domperidone 30 mg. No significant adverse events were reported. A reduction in pain intensity and nausea was noted but this was not statistically significant. It was concluded that domperidone shortens the duration of a migraine attack and may help reduce headache and associated symptoms.